A multicenter, controlled, prospective endpoint trial confirmed that routinely taking blood pressure (BP)-lowering medications at bedtime, as opposed to upon waking, resulted in improved ambulatory BP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and markedly reduced major cardiovascular disease (CVD) events. The trial included 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) assigned (1:1) to take the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory BP monitoring was performed for 48 h. During a 6.3-year median follow-up, 1752 patients experienced the primary CVD outcome. Adjusted for significant influential characteristics, patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio of the primary CVD outcome (0.55) and each of its single components, i.e. CVD death (0.44), myocardial infarction (0.66), coronary revascularization (0.60), heart failure (0.58), and stroke (0.51). The bedtime treatment was at least as safe, and with similar patient compliance and adherence, as usual upon-waking treatment. The findings are consistent with previous studies. Source: https://academic.oup.com/eurheartj/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.